Prescient Therapeutics Limited · ASX:PTX
Prescient Therapeutics — Shareholder Meeting (November 2020)
32 slides from Prescient Therapeutics's shareholder meeting presentation, Nov 24, 2020
Slide 1: A Year of Transformation – Annual General Meeting
For personal use only A YEAR OF TRANSFORMATION Annual General Meeting November 2020
Slide 2: Disclaimer and Safe Harbor
DISCLAIMER AND SAFE HARBOR Certain statements made in this document are forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements are not historical facts but rather are based on
Slide 3: Executive Summary
Executive Summary For personal use only • Year of transformation • Transformative licenses from UPenn and Oxford to create OmniCAR platform for next-gen CAR-T • Navigating challenges & uncertainty of COVID-19 • Catapults PTX to the forefront of CAR-T • Progression of PTX-200 in AML innovation • Enco
Slide 4: An Expanded & Innovative Pipeline
An Expanded & Innovative Pipeline For personal use only Targeted Therapies 4
Slide 5: A productive months yielding many achievements
A productive 12 months yielding many achievements PTX-100 Progresses For personal use only to Next Dose; PTX Signs Next Gen Adds New Site CAR-T Platform From PTX-200 AML Trial Encouraging Data UPenn and Oxford Progresses to From Ovarian Trial Next Dose Level $13.5m raised in oversubscribed SPP & 1st
Slide 6: Overcoming challenges in tough year
Overcoming challenges in tough year PTX-100 trial – a great For personal use only COVID-19 Travel & Conferences “problem” to have! • No specific and material disruptions, but impossible to escape its impact • Patients are staying on therapy • Industry has adjusted well to virtual much longer (and at
Slide 7: PTX-100 First in Class, First in Man
For personal use only PTX-100 FIRST IN CLASS, FIRST IN MAN GGT-1 INHIBITOR OF RAS PATHWAY 7
Slide 8: PTX-100 Executive Summary
PTX-100 Executive Summary For personal use only First in Class inhibitor of Clinical Status Ras pathway • Phase 1 advanced solid tumor complete (safe; clinical activity) • Downstream MoA captures many Ras mutant variants • Phase 1b PK/PD Basket trial underway • PTX-100 is only RhoA inhibitor in clin
Slide 9: PTX-100 Addresses Many Types of Ras Mutations
PTX-100 ADDRESSES MANY TYPES OF RAS MUTATIONS For personal use only 3 types of 80% of cancer Ras cancer patients harbour Ras more than one Ras mutation! Competitor drugs are targeting one very specific type of Ras mutation • KRAS G12C • This approach can lead to underwhelming responses and/or relaps
Slide 10: PTX-100 Phase 1b Basket Study Underway
PTX-100 PHASE 1B BASKET STUDY UNDERWAY Phase 1 trial in solid tumours completed – safety profile established. For personal use only Now focussing on Ras and Rho mutant cancers. PTX-100 has a unique position in Ras and RhoA mutant malignancies Phase 1b PK/PD commenced Basket trial of: • Gastric cance
Slide 11: PTX-200 Novel AKT Inhibition
For personal use only PTX-200 NOVEL AKT INHIBITION OVERCOMING KINASE PROMISCUITY & LIMITATIONS OF PREVIOUS ATTEMPTS AT AKT INHIBITION 11
Slide 12: PTX-200 Executive Summary
PTX-200 Executive Summary For personal use only Novel PH Domain Clinical Status & Akt inhibition • Clinical PoC established • Unique MoA (not a kinase • Her2- Breast cancer Ph2a: ORR 91% inhibitor) including 3 CRs. Responses durable. ZNF217 biomarker. • Selectively kills tumors with hyperactivated A
Slide 13: Phase 1b Trial Underway: Acute Myeloid Leukemia
PHASE 1B TRIAL UNDERWAY: ACUTE MYELOID LEUKEMIA For personal use only Building upon encouraging Phase 1 results with PTX-200 (monotherapy) PI Professor Jeff Lancet at Moffitt, with Dr Tara Lin at KUMC 15 patients with cytarabine held constant at 200-400 mg/m2 as continuous infusion » 3 CRs so far Je
Slide 14: Universal, Next Generation CAR-T
For personal use only Universal, Next Generation CAR-T 14
Slide 15: CAR-T: A genuine turning point in cancer treatment
CAR-T: A genuine turning point in cancer treatment For personal use only At ASCO 2020 (June) Johnson & Johnson presented an update on their CAR-T therapy for multiple myeloma “CAR T represents a turning point The overall response rate (ORR) was 100% in the history of human medicine, a genuine revolu
Slide 16: How does the CAR-T process work?
How does the CAR-T process work? For personal use only 1. 2. Blood is collected from the T- Cells are separated and patient removed 3. T-Cells are genetically altered to have special 5. cancer-recognising receptors called Chimeric Patient first receives Antigen Receptor (CAR) Chemotherapy, and then
Slide 17: Key Challenges Confronting the field of CAR-T
Key Challenges Confronting the field of CAR-T For personal use only Time and Cost Safety No Control Targets Escape of delivering CAR-T can have Clinicians have no Finding targets that Antigen loss treatment serious safety control of cells post work; leads to relapse concerns infusion Antigen heterog
Slide 18: How OmniCAR works
How OmniCAR works 1 2 3 For personal use only Unarmed CAR-T cells are Separate administration Armed CAR-T cells are administered to patient of targeting ligand activated, resulting in on- viable but inactive results in a complete, demand tumour killing armed CAR-T cell Targeting ligand On-demand tum
Slide 19: OmniCAR can do what conventional CAR-T cannot
OmniCAR can do what conventional CAR-T cannot For personal use only Conventional CAR-T Can be given any map; Armed with any weapon Multiple deployments Including several at once • Soldier with only one map • Single weapon Full communication and • Only trained to hit one target control at all times,
Slide 20: Overcoming Clinical Limitations of CAR-T
Overcoming Clinical Limitations of CAR-T Universal CAR-T Clinical Challenges Conventional CAR-T (OmniCAR) For personal use only On-demand activation of CAR-T cell Controlling CAR-T cell activity post infusion Control serious side effects (TLS; CRS) (preventative and responsive) Ability t
Slide 21: Safety: Ability Control Dose & Activity
Safety: Ability Control Dose & Activity Conventional CAR-T For personal use only CAR-T BINDER DOSE DOSE TOXICITY TOXICITY EFFICACY EFFICACY Concept to be tested in human under well controlled clinical trial(s) in compliance with regulatory requirements. 21
Slide 22: Safety: Built-in on/off switch
Safety: Built-in on/off switch For personal use only BINDER DOSE TOXICITY EFFICACY Stop Can safely administering recommence dosing binder Concept to be tested in human under well controlled clinical trial(s) in compliance with regulatory requirements. 22
Slide 23: Ability to Target Multiple Antigens Sequentially
Ability to Target Multiple Antigens Sequentially For personal use only OmniCAR directed at OmniCAR now cancer antigen 1 directed at cancer antigen 2 Cancer mutates Concept to be tested in human under well controlled clinical trial(s) in compliance with regulatory requirements. 23
Slide 24: Ability to Target Multiple Antigens Simultaneously
Ability to Target Multiple Antigens Simultaneously For personal use only OmniCAR directed at multiple cancer antigens Cancers with heterogenous antigens Concept to be tested in human under well controlled clinical trial(s) in compliance with regulatory requirements. 24
Slide 25: With OmniCAR, this is just the start for CAR-T
With OmniCAR, this is just the start for CAR-T For personal use only Current generation CAR-T • Seeking to enhance current generation CAR-Ts…. • Autologous T cells • B-cell malignancies • …& more significantly, help realise the broader potential of CAR-T, which is much bigger opportunity! Cell types
Slide 26: OmniCAR Platform Business Model
OmniCAR Platform Business Model Potential partner For personal use only Target 1 PTX next gen Potential partner CAR-T 1 Target 2 Collaborate & Next generation license to third products in-house parties Potential partner specific construct 1 PTX next gen CAR-T 2 Potential partner Potential partner ce
Slide 27: CAR-T deal activity
CAR-T deal activity Bought for For personal use only US$11.9B Aug 2017 First generation CAR-T… Bought for Bought for US$9B US$74B Jan 2018 Nov 2019 Bought for US$665M …now Dec 2019 next generation CAR-T (US$120M upfront) (Pre-clinical peer) ajmc.com, 2018 27
Slide 28: Thorough strategic review for internal OmniCAR programs
Thorough strategic review for internal OmniCAR programs For personal use only INTERNAL PTX LEADERSHIP INVENTORS Medical, Scientific; Clinical; BD Cell biology; CAR-T; UIRs; protein engineering ANTIBODY EXPERTS Important in the consideration of CLINICIANS & KOLs binding domains of OmniCAR Global thou
Slide 29: Current Activities
Current Activities TARGETED THERAPIES OmniCAR For personal use only • PTX-100: Ph1b basket study underway • Currently undertaking strategic review of opportunities for in- house programs • PTX-200: • 1-2 lead programs • AML: Ph1b underway • Follow-on programs exploiting different OmniCAR • Evaluatin
Slide 30: In the next months we will work towards
In the next 12 months we will work towards: For personal use only • Ongoing business development activities • PTX-200 AML completion of Ph1b • Continuing to build awareness among new dosing schedule investors, clinicians and corporates • Provisional results of Cell Therapy Enhancement programs • Com
Slide 31: Compelling investment case!
Compelling investment case! For personal use only Best in class, unique platform. Well funded to deliver value- Enviably positioned ahead of a adding milestones huge wave in CAR-T Many shots on goal for Creating next generation CAR-T substantial value creation products for Prescient Two differentiat
Slide 32: Thank you!
For personal use only Thank you! ASX code: PTX www.ptxtherapeutics.com
Prescient Therapeutics — Shareholder Meeting (November 2020) on 6ix